BBIO vs LEN · rev $221.9M vs rev $34.19B
BridgeBio Pharma Inc (BBIO) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
BBIO currently screens at market cap $13.24B. LEN currently screens at market cap $0.
Not investment advice. Open the BBIO and LEN stock pages for the full models.
Not investment advice.